Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biotinol-5'-AMP is a synthetic small molecule that mimics the natural reaction intermediate of biotin protein ligase (BPL), an enzyme essential for bacterial metabolism. Structurally, it is a derivative of adenosine monophosphate (AMP) conjugated to a biotin analog. Biotinol-5'-AMP acts as a pan inhibitor of BPLs from various clinically important bacteria, including *Staphylococcus aureus* and *Mycobacterium tuberculosis*. It competitively inhibits the substrate biotin at the enzyme's active site, thereby blocking the ligation of biotin to target proteins—a process critical for fatty acid synthesis in bacteria. This compound has demonstrated antibacterial activity with low micromolar minimum inhibitory concentrations (MICs) against these pathogens and shows no cytotoxicity toward human HepG2 cells[1][6][7]. It is not approved for clinical use but serves as an important tool in biochemical research and drug discovery targeting bacterial BPL.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on biotinol-5-amp.